ACCELERATE DIAGNOSTICS INC(AXDXQ.US)

Company Encyclopedia

ACCELERATE DIAGNOSTICS INC

AXDXQ.US

1.353 T

AXDXQ.USMarket value -Rank by Market Cap -/-

Financial Score

28/01/2026 Update

Health Care EquipmentIndustry

Industry Ranking166/176

Industry medianC

Industry averageC

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreB
- ROE131.82%A
- Profit Margin-427.81%E
- Gross Margin23.12%D
Growth ScoreD
- Revenue YoY-2.99%D
- Net Profit YoY18.78%B
- Total Assets YoY-8.96%E
- Net Assets YoY-181.78%E
Cash ScoreD
- Cash Flow Margin-23.37%D
- OCF YoY-2.99%D
Operating ScoreC
- Turnover0.39C
Debt ScoreE
- Gearing Ratio296.25%E

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

Accelerate Diagnostics Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures

Accelerate Diagnostics Inc. is facing delisting from the Nasdaq Stock Market following its voluntary Chapter 11 bankruptcy filing on May 8, 2025. The company received a delisting notice due to public interest concerns and failure to meet minimum bid price and market value requirements. Its stock, consistently below $1.00 per share, will be suspended from trading on May 15, 2025, and is expected to transition to the over-the-counter market as "AXDXQ," though trading is not guaranteed. The company will not appeal the delisting decision.

Reuters·05/13/2025 04:17

Reuters·05/13/2025 04:17

BRIEF-Accelerate Diagnostics files for Chapter 11 bankruptcy

BRIEF-Accelerate Diagnostics files for Chapter 11 bankruptcyMay 8 (Reuters) - Accelerate ceo says the company plans a sale of assets through a court-supervised auction, has a stalking-horse bidder, and hopes to close within 90 days, court records showAccelerate diagnostics files for chapter 11 bankruptcy protection in delaware, court records showAccelerate says it had $28.6 million assets, $84.6 million debts as of december 31, 2024Accelerate says it has faced headwinds including the covid-19 pandemic, regulatory headwinds, too much debt, unfavorable capital markets, and competition

Reuters·05/08/2025 20:18

Reuters·05/08/2025 20:18

Accelerate Diagnostics Inc. Files Initial Statement of Beneficial Ownership for Director Paul Shalhoub

Accelerate Diagnostics Inc. has filed an initial statement of beneficial ownership for its Director, Paul Vincent Shalhoub. The filing provides details regarding his ownership stake in the company. The full document is accessible via the U.S. Securities and Exchange Commission's EDGAR system. This news brief is generated by Public Technologies and is intended for informational purposes only, not as financial or legal advice.

Reuters·05/02/2025 06:41

Reuters·05/02/2025 06:41

Accelerate Diagnostics CEO Sells Shares to Cover Tax Obligations

Reporter NamePhillips JackRelationshipChief Executive OfficerTypeSellAmount$16,472SEC FilingForm 4Phillips Jack, Chief Executive Officer and Director of Accelerate Diagnostics, sold 25,343 shares of Common Stock on April 4, 2025, at a price of $0.65 per share, totaling $16,472. This sale was to cover tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Jack directly owns 191,374 shares of Accelerate Diagnostics.SEC Filing: Accelerate Diagnostics, Inc [ AXDX ] - Form 4 - Apr. 07, 2025

TradingView·04/08/2025 07:40

TradingView·04/08/2025 07:40

Accelerate Diagnostics Inc reports results for the quarter ended December 31 - Earnings Summary

Accelerate Diagnostics IncQ) reported a quarterly adjusted loss of 38 cents per share for the quarter ended December 31, an improvement from a loss of 81 cents per share in the same quarter last year. Revenue decreased by 7% to $2.82 million, below the expected $3.02 million. The company's shares fell by 19.2% this quarter. Analysts maintain a "strong buy" rating, with no changes in earnings estimates over the last three months.

Reuters·03/26/2025 20:00

Reuters·03/26/2025 20:00